Center for Scientific Review; Amended Notice of Meeting, 15211 [2024-04306]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 42 / Friday, March 1, 2024 / Notices
ddrumheller on DSK120RN23PROD with NOTICES1
context can demonstrate which
oncogene derived neoepitopes are
presented by common HLA alleles, and
can provide the data necessary to
rapidly develop TCRs against the
desired antigens.
Using the MS approach, inventors at
the National Cancer Institute (NCI) have
identified neoepitopes derived from a
mutated isoform of Epithelial Growth
Factor Receptor (EGFR) presented by
HLA A*11:01 across multiple biological
replicates. From this MS data, the
inventors were able to successfully
isolate murine TCRs that specifically
recognize HLA A*11:01 restricted
neoepitopes targeting EGFR L858R.
According to various cancer genome
databases, EGFR L858R is highly
prevalent in lung adenocarcinoma, nonsmall cell lung carcinoma, and nonsquamous non-small cell lung
carcinoma, making this driver mutation
an excellent target to develop off-theshelf cellular therapies. The clinical
potential of these TCRs has not been
explored.
Therapeutic Area(s): Cancer.
Research uses include: TCRs may be
used as positive controls to identify
HLA–A*11:01 EGFR L858R reactive T
cells from different sources such as
patients or animal models; TCRs
recognize the common EGFR L858R
driver mutation in the context of HLA–
A*11:01; EGFR; the prevalence of EGFR
L858R substitutions, relative to the
overall EGFR mutation population,
ranges from 27.7% to 41.1% in nonsmall cell lung cancer patients; HLA–
A*11:01 allele frequency is particularly
high (up to 60%) in Asian and Oceanian
populations. This research has validated
the effectiveness of using mass
spectrometry to detect amino acid
sequences on specific HLA complexes.
Achieving expeditious
commercialization of federally funded
research and development is consistent
with the goals of the Bayh-Dole Act,
codified as 35 U.S.C. 200–212 and 37
CFR 404.4.
Development Stage: Research Tool.
Dated: February 26, 2024.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2024–04251 Filed 2–29–24; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
21:28 Feb 29, 2024
Jkt 262001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Population Sciences
and Epidemiology Integrated Review
Group, Aging, Injury, Musculoskeletal,
and Rheumatologic Disorders Study
Section, March 14, 2024, 09:00 a.m. to
March 15, 2024, 08:00 p.m., National
Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892
which was published in the Federal
Register on February 26, 2024, 89 FR
14081, Doc 2024–03762.
This meeting is being amended to
change the location to Hilton
Alexandria Old Town, 1767 King Street,
Alexandria, VA 22314. The meeting
time will remain the same. The meeting
is closed to the public.
Dated: February 26, 2024.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–04306 Filed 2–29–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine and Oral
Fluid Drug Testing for Federal
Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
The Department of Health and
Human Services (HHS) notifies Federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITFs) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines) using
Urine and the laboratories currently
certified to meet the standards of the
Mandatory Guidelines using Oral Fluid.
FOR FURTHER INFORMATION CONTACT:
Anastasia Flanagan, Division of
Workplace Programs, SAMHSA/CSAP,
5600 Fishers Lane, Room 16N06B,
Rockville, Maryland 20857; 240–276–
2600 (voice); Anastasia.Flanagan@
samhsa.hhs.gov (email).
SUMMARY:
PO 00000
Frm 00096
Fmt 4703
Sfmt 4703
15211
The
Department of Health and Human
Services (HHS) publishes a notice
listing all HHS-certified laboratories and
Instrumented Initial Testing Facilities
(IITFs) in the Federal Register during
the first week of each month, in
accordance with Section 9.19 of the
Mandatory Guidelines for Federal
Workplace Drug Testing Programs
(Mandatory Guidelines) using Urine and
Section 9.17 of the Mandatory
Guidelines using Oral Fluid. If any
laboratory or IITF certification is
suspended or revoked, the laboratory or
IITF will be omitted from subsequent
lists until such time as it is restored to
full certification under the Mandatory
Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
internet at https://www.samhsa.gov/
workplace/drug-testing-resources/
certified-lab-list.
HHS separately notifies Federal
agencies of the laboratories and IITFs
currently certified to meet the standards
of the Mandatory Guidelines using
Urine and of the laboratories currently
certified to meet the standards of the
Mandatory Guidelines using Oral Fluid.
The Mandatory Guidelines using
Urine were first published in the
Federal Register on April 11, 1988 (53
FR 11970), and subsequently revised in
the Federal Register on June 9, 1994 (59
FR 29908); September 30, 1997 (62 FR
51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858);
December 10, 2008 (73 FR 75122); April
30, 2010 (75 FR 22809); January 23,
2017 (82 FR 7920); and on October 12,
2023 (88 FR 70768).
The Mandatory Guidelines using Oral
Fluid were first published in the
Federal Register on October 25, 2019
(84 FR 57554) with an effective date of
January 1, 2020, and subsequently
revised in the Federal Register on
October 12, 2023 (88 FR 70814).
The Mandatory Guidelines were
initially developed in accordance with
Executive Order 12564 and section 503
of Public Law 100–71 and allowed urine
drug testing only. The Mandatory
Guidelines using Urine have since been
revised, and new Mandatory Guidelines
allowing for oral fluid drug testing have
been published. The Mandatory
Guidelines require strict standards that
laboratories and IITFs must meet in
order to conduct drug and specimen
validity tests on specimens for Federal
SUPPLEMENTARY INFORMATION:
E:\FR\FM\01MRN1.SGM
01MRN1
]]>Agencies
[Federal Register Volume 89, Number 42 (Friday, March 1, 2024)]
[Notices]
[Page 15211]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-04306]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Amended Notice of Meeting
Notice is hereby given of a change in the meeting of the Population
Sciences and Epidemiology Integrated Review Group, Aging, Injury,
Musculoskeletal, and Rheumatologic Disorders Study Section, March 14,
2024, 09:00 a.m. to March 15, 2024, 08:00 p.m., National Institutes of
Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 which
was published in the Federal Register on February 26, 2024, 89 FR
14081, Doc 2024-03762.
This meeting is being amended to change the location to Hilton
Alexandria Old Town, 1767 King Street, Alexandria, VA 22314. The
meeting time will remain the same. The meeting is closed to the public.
Dated: February 26, 2024.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-04306 Filed 2-29-24; 8:45 am]
BILLING CODE 4140-01-P
